[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612893":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":49,"collaborators":52,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":77,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Pisa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Elderly, non-autonomous Patients",null,"Adult participants fulfilling the following inclusion criteria: fluency in Italian language, age higher than 64 years, loss of autonomies of daily living as assessed by the Katz Activities of Daily Living or in the Lawton Instrumental Activities of Daily Living questionnaires, having performed blood exams and a head neuroimaging feasable for cerebrovascular burden assessment, i.e., Magnetic Resonance Imaging (MRI) or computed tomography (CT), in the 6 months prior to recruitment.",[13],"Diagnostic Test: Plasma phosphorylated Tau 181",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Plasma phosphorylated Tau 181","Plasma will be collected in dipotassium EDTA tubes at recruitment and centrifugated at 1800-2000xg for 10 minutes within a short data frame. Plasma will be subsequently aliquoted and stored at -80°C. Immediately prior to analysis, samples will be thawed at room temperature, vortexed, and centrifuged. Plasma p-tau181 concentrations will be then quantified using a fully automated chemiluminescent enzyme immunoassay on the LUMIPULSE G600II system, in accordance with the manufacturer's instructions.",[9],[21],{"name":22,"affiliation":5,"role":23},"Gabriele Siciliano, Professor, MD, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Francesco Turco, MD, PhD","CONTACT","+39-050992905","francesco.turco@phd.unipi.it",[31],{"facility":32,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Azienda Ospedaliera Universitaria Pisana","RECRUITING","Pisa","56126","Italy","IT",{"type":39,"coordinates":40},"Point",[41,42],10.4036,43.70853,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":10,"email":48},"Benedetta Becherini, M.A.","+39-050996418","clinicaltrial.center@ao-pisa.toscana.it",{"type":23,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Gabriele Siciliano","Professor, MD, PhD",[53],{"name":54,"class":6},"Azienda Ospedaliero, Universitaria Pisana","100612893","predictors-of-emergency-department-use-in-frail-patients-100612893",false,"NCT07259499","Predictors of Emergency Department Use in Frail Patients","Towards an Integrated Care System for the Assistance of Patients With Chronic Diseases, Multimorbidity, Frailty, and Polypharmacy","THE-Spoke 10","Inclusion Criteria:\n\n* fluency in Italian language,\n* age higher than 64 years,\n* loss of autonomies of daily living as assessed by the Katz Activities of Daily Living or in the Lawton Instrumental Activities of Daily Living questionnaires,\n* having performed routinary blood exams in the 6 months prior to recruitment\n* having performed head neuroimaging feasable for cerebrovascular burden assessment, i.e., Magnetic Resonance Imaging (MRI) or computed tomography (CT), in the 6 months prior to recruitment.\n\nExclusion Criteria:\n\n* withdrawal of the informed consent","ALL","65 Years",{"count":66,"type":67},110,"ESTIMATED","OBSERVATIONAL","When admitted to the emergency department (ED), elderly non-autonomous patients show high risk of adverse health outcomes. The prompt identification of ED use risk factors in such population is hence needed. While cognitive impairment is a known clinical risk factor, biomarkers of most prevalent dementias have been scarcely investigated as possible ED use predictors. Within this context, this prospective study aims at exploring whether plasma phospho-tau181 and cerebrovascular burden can predict ED use at 6 months in elderly non-autonomous patients, irrespective of frailty.",[71,72,73,74,75,76],"Alzheimer s Disease","Vascular Dementia","Frailty","Elderly","Emergency Department Visits","Autonomy",[78,79,80,73,81,74,82],"phosphorylated tau 181","dementia","Emergency Department","Autonomies","cerebrovascular","2025-11-20",{"date":85,"type":86},"2025-12-02","ACTUAL",{"date":88,"type":86},"2023-11-19",{"date":90,"type":67},"2025-12-31",{"name":5,"class":6},1]